Literature DB >> 24615654

Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.

Takashi Hamakawa1, Shoichi Sasaki, Yasuhiro Shibata, Makoto Imura, Yasue Kubota, Yoshiyuki Kojima, Kenjiro Kohri.   

Abstract

BACKGROUND: Although inflammation plays an important role in the development of benign prostatic hyperplasia (BPH), little is known about the exact mechanism underlying this pathogenesis. Here, we investigated the relationship between the inflammatory reaction and BPH.
METHODS: cDNA microarray analysis was used to identify changes in inflammation-related gene expression in a recently established rat model that mimics human BPH. To investigate the genes identified in the analysis, quantitative (q)RT-PCR, Western blotting, immunostaining, and a cell proliferation assay were conducted using BPH model tissues, human prostate tissues, and normal human prostate cultured cells.
RESULTS: Of the 31,100 genes identified in the cDNA analysis, seven inflammatory-response-related genes were expressed at a >2-fold higher level in rat BPH tissues than in normal rat prostate tissues. The levels of the most commonly expressed pro-inflammatory cytokine, IL-18, significantly increased in rat BPH tissues. In humans, IL-18 was localized in the epithelial and stromal components, while its receptor was strongly localized in smooth muscle cells. Furthermore, in human prostate smooth muscle cell line (PrSMC), IL-18 effected dose-dependent increases in the phosphorylated Akt and thrombospondin-1 (TSP-1) levels. TSP-1 promoted proliferation of the human prostate stromal cells (PrSC).
CONCLUSIONS: IL-18 may act directly in BPH pathogenesis by inducing TSP-1 production in prostatic smooth muscle cells via Akt phosphorylation.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL-18; TSP-1; benign prostatic hyperplasia; inflammation

Mesh:

Substances:

Year:  2014        PMID: 24615654     DOI: 10.1002/pros.22773

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

Review 1.  Inflammasomes in the urinary tract: a disease-based review.

Authors:  J Todd Purves; F Monty Hughes
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-11

Review 2.  Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Fabrizio Presicce; Andrea Tubaro
Journal:  Nat Rev Urol       Date:  2016-09-30       Impact factor: 14.432

3.  Inflammasomes are important mediators of prostatic inflammation associated with BPH.

Authors:  Mahendra Kashyap; Subrata Pore; Zhou Wang; Jeffrey Gingrich; Naoki Yoshimura; Pradeep Tyagi
Journal:  J Inflamm (Lond)       Date:  2015-05-17       Impact factor: 4.981

4.  Tadalafil Treatment Improves Inflammation, Cognitive Function, And Mismatch Negativity Of Patients With Low Urinary Tract Symptoms And Erectile Dysfunction.

Authors:  Amparo Urios; Felipe Ordoño; Raquel García-García; Alba Mangas-Losada; Paola Leone; Juan José Gallego; Andrea Cabrera-Pastor; Javier Megías; Juan Fermin Ordoño; Vicente Felipo; Carmina Montoliu
Journal:  Sci Rep       Date:  2019-11-19       Impact factor: 4.379

5.  Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia.

Authors:  Cosimo De Nunzio; Simona Giglio; Antonella Stoppacciaro; Mauro Gacci; Roberto Cirombella; Emidio Luciani; Andrea Tubaro; Andrea Vecchione
Journal:  Oncotarget       Date:  2017-02-07

6.  Serum omentin-1 level in patients with benign prostatic hyperplasia.

Authors:  Haiqing He; Shuiqing Wu; Jun Hao; Long Wang; Kai Ai; Xuan Zhu; Ran Xu; Xiaokun Zhao; Yinhuai Wang; Zhaohui Zhong
Journal:  BMC Urol       Date:  2020-05-06       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.